for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Harrow Health Inc

HROW.OQ

Latest Trade

5.22USD

Change

-0.06(-1.14%)

Volume

30,061

Today's Range

5.16

 - 

5.33

52 Week Range

3.38

 - 

8.25

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
5.28
Open
5.33
Volume
30,061
3M AVG Volume
4.31
Today's High
5.33
Today's Low
5.16
52 Week High
8.25
52 Week Low
3.38
Shares Out (MIL)
25.62
Market Cap (MIL)
135.27
Forward P/E
-8.52
Dividend (Yield %)
--

Next Event

Q2 2020 Harrow Health Inc Earnings Release

Latest Developments

More

Harrow Health Says Still Have No Interest In Or Need To Sell Co's Stock To Raise Capital

Harrow Health Says Issues Statement On Novel Drug Solutions & Eye Care Northwest's Press Release Containing Statements About Co

Harrow Health, Allergan Filed Joint Stipulation To Voluntarily Dismiss Pending Appeals

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Harrow Health Inc

Harrow Health, Inc., formerly Imprimis Pharmaceuticals, Inc., owns diversified portfolio of healthcare businesses. The Company’s subsidiaries are Imprimis Pharmaceuticals Inc. and Park Compounding. Imprimis Pharmaceuticals Inc. is engaged in ophthalmology pharmaceutical compounding business. Park Compounding is engaged in compounding business and also offers strategic research and development facilities, which is engaged in developing and dispensing medicines for individual patients.

Industry

Major Drugs

Contact Info

102 WOODMONT BLVD, SUITE 610

NASHVILLE, TN

37215

United States

+1.615.7334731

http://www.imprimisrx.com/

Executive Leadership

Robert J. Kammer

Independent Chairman of the Board

Mark L. Baum

Chief Executive Officer, Director

Andrew R. Boll

Chief Financial Officer, Corporate Secretary

John P. Saharek

President of ImprimisRx

Larry Dillaha

Chief Medical Officer

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.1K

2020(E)

0.0K
EPS (USD)

2018

0.610

2019

0.010

2020(E)

-0.620
Price To Earnings (TTM)
--
Price To Sales (TTM)
2.67
Price To Book (MRQ)
8.82
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
92.47
LT Debt To Equity (MRQ)
75.82
Return on Investment (TTM)
-54.60
Return on Equity (TTM)
-43.00

Latest News

Latest News

BRIEF-ImprimisRx Announces Exclusive Agreement With Doxy.Me To Provide Healthcare Professionals With Telemedicine Services

* IMPRIMISRX® ANNOUNCES EXCLUSIVE AGREEMENT WITH DOXY.ME TO PROVIDE HEALTHCARE PROFESSIONALS WITH TELEMEDICINE SERVICES Source text for Eikon: Further company coverage:

BRIEF-Harrow Health Says Still Have No Interest In Or Need To Sell Co's Stock To Raise Capital

* HARROW HEALTH INC - STILL HAVE NO INTEREST IN OR NEED TO SELL CO'S STOCK TO RAISE CAPITAL

BRIEF-Imprimisrx Announces Supply Agreement With Eyecare Services Partners

* IMPRIMISRX® ANNOUNCES SUPPLY AGREEMENT WITH EYECARE SERVICES PARTNERS

BRIEF-ImprimisRx Announces Supply Agreement With iOR Partners

* IMPRIMISRX® ANNOUNCES SUPPLY AGREEMENT WITH IOR PARTNERS Source text for Eikon: Further company coverage:

BRIEF-ImprimisRx Announces Supply Agreement With Vision Center Network Of America

* IMPRIMISRX® ANNOUNCES SUPPLY AGREEMENT WITH VISION CENTER NETWORK OF AMERICA (VCNA)

Allergan wins less than $50,000 in case against compounder Imprimis

A federal jury on Thursday awarded Allergan PLC less than $50,000 of the millions of dollars it sought in a false advertising lawsuit seeking to stop Imprimis Pharmaceuticals Inc from selling certain compounded drugs that bypass regulatory approval, including a cheaper alternative...

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up